soul trial oral semaglutide cardiovascular outcomes soul trial results Forecasting Milestones: A Predictive Analysis for Early Termination of the Study | Diabetes Therapy soul trial oral semaglutide cardiovascular

Many competitors take longer, sometimes requiring several stages of assessment or lab results before a prescription is issued

We adjust the titration schedule rather than push through

Ozempic Blood Clot Locations Research indicates that the active ingredient in Ozempic, semaglutide, may increase a persons risk of developing blood clots

Do not use Semaglutide if: you are allergic to the medication, or you have: multiple endocrine neoplasia type 2

Links to Relevant Resources References Dalsgaard, N.B., Brnden, A., Vilsbll, T., Knop, F.K

Dose may be increased to 9 mg once daily if additional glycemic control is needed after at least 30 days on the 4 mg dose